UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
April 11, 2024 23:07 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Inc.’s 2024 Female Founders list highlights why female founders are always a good bet
April 09, 2024 12:19 ET
|
Adyn, Inc.
Inc’s 2024 Female Founders list highlights why female founders are always a good bet. adyn founder, Elizabeth Ruzzo, is named to the list.
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
April 05, 2024 16:21 ET
|
Predicine
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
April 05, 2024 16:10 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
April 05, 2024 02:08 ET
|
Predicine
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting...
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
January 08, 2024 12:01 ET
|
Predicine
Collaboration Utilizing PredicineCARE™ Urine cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Comprise named top agency in several business, PR and marketing awards programs
December 19, 2023 06:00 ET
|
Comprise
Boulder, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Comprise® solidified its status as a leading communications agency delivering integrated public relations and digital marketing services with the...
Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC
December 11, 2023 15:12 ET
|
Predicine
HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib...
Predicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023
October 17, 2023 13:58 ET
|
Predicine
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid,...
Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib
September 20, 2023 13:12 ET
|
Predicine
HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine (NEJM),...